Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | PI103 | 3 | 72 | 0.1 | 2784.5 | 3311.5 | 586.9 | -1.0 | 0.866 | 0.841 | 2.496 | BT20 PI103 0 3 |
| BT-20 | PI103 | 3 | 72 | 0.32 | 1802.8 | 3311.5 | 586.9 | -0.495 | 0.568 | 0.544 | 2.496 | BT20 PI103 0 3 |
| BT-20 | PI103 | 3 | 72 | 1.0 | 851.5 | 3311.5 | 586.9 | 0.0 | 0.161 | 0.257 | 2.496 | BT20 PI103 0 3 |
| BT-20 | PI103 | 3 | 72 | 3.2 | 607.5 | 3311.5 | 586.9 | 0.505 | 0.014 | 0.183 | 2.496 | BT20 PI103 0 3 |
| BT-20 | PIK-93 | 3 | 72 | 0.001 | 3242.8 | 3394.0 | 586.9 | -3.0 | 0.964 | 0.955 | 2.532 | BT20 PIK93 0 3 |
| BT-20 | PIK-93 | 3 | 72 | 0.0032 | 3404.3 | 3394.0 | 586.9 | -2.49 | 1.000 | 1.000 | 2.532 | BT20 PIK93 0 3 |
| BT-20 | PIK-93 | 3 | 72 | 0.01 | 3291.3 | 3394.0 | 586.9 | -2.0 | 0.976 | 0.970 | 2.532 | BT20 PIK93 0 3 |
| BT-20 | PIK-93 | 3 | 72 | 0.032 | 3158.3 | 3394.0 | 586.9 | -1.49 | 0.944 | 0.931 | 2.532 | BT20 PIK93 0 3 |
| BT-20 | PIK-93 | 3 | 72 | 0.1 | 3360.3 | 3394.0 | 586.9 | -1.0 | 0.992 | 0.990 | 2.532 | BT20 PIK93 0 3 |
| BT-20 | PIK-93 | 3 | 72 | 0.32 | 3052.8 | 3394.0 | 586.9 | -0.495 | 0.918 | 0.899 | 2.532 | BT20 PIK93 0 3 |
| BT-20 | PIK-93 | 3 | 72 | 1.0 | 2595.5 | 3394.0 | 586.9 | 0.0 | 0.799 | 0.765 | 2.532 | BT20 PIK93 0 3 |
| BT-20 | PIK-93 | 3 | 72 | 3.2 | 1424.3 | 3394.0 | 586.9 | 0.505 | 0.419 | 0.420 | 2.532 | BT20 PIK93 0 3 |
| BT-20 | Sirolimus | 3 | 72 | 0.001 | 1665.3 | 3288.5 | 586.9 | -3.0 | 0.521 | 0.506 | 2.486 | BT20 Rapamycin 0 3 |
| BT-20 | Sirolimus | 3 | 72 | 0.0032 | 1578.5 | 3288.5 | 586.9 | -2.49 | 0.489 | 0.480 | 2.486 | BT20 Rapamycin 0 3 |
| BT-20 | Sirolimus | 3 | 72 | 0.01 | 1697.3 | 3288.5 | 586.9 | -2.0 | 0.533 | 0.516 | 2.486 | BT20 Rapamycin 0 3 |
| BT-20 | Sirolimus | 3 | 72 | 0.032 | 1493.5 | 3288.5 | 586.9 | -1.49 | 0.456 | 0.454 | 2.486 | BT20 Rapamycin 0 3 |
| BT-20 | Sirolimus | 3 | 72 | 0.1 | 1592.5 | 3288.5 | 586.9 | -1.0 | 0.494 | 0.484 | 2.486 | BT20 Rapamycin 0 3 |
| BT-20 | Sirolimus | 3 | 72 | 0.32 | 1747.8 | 3288.5 | 586.9 | -0.495 | 0.551 | 0.531 | 2.486 | BT20 Rapamycin 0 3 |
| BT-20 | Sirolimus | 3 | 72 | 1.0 | 1499.8 | 3288.5 | 586.9 | 0.0 | 0.458 | 0.456 | 2.486 | BT20 Rapamycin 0 3 |
| BT-20 | Sirolimus | 3 | 72 | 3.2 | 1352.8 | 3288.5 | 586.9 | 0.505 | 0.399 | 0.411 | 2.486 | BT20 Rapamycin 0 3 |
| BT-20 | TGX221 | 3 | 72 | 0.001 | 2926.0 | 3248.8 | 586.9 | -3.0 | 0.917 | 0.901 | 2.469 | BT20 TGX221 0 3 |
| BT-20 | TGX221 | 3 | 72 | 0.0032 | 3078.0 | 3248.8 | 586.9 | -2.49 | 0.957 | 0.947 | 2.469 | BT20 TGX221 0 3 |
| BT-20 | TGX221 | 3 | 72 | 0.01 | 3184.8 | 3248.8 | 586.9 | -2.0 | 0.984 | 0.980 | 2.469 | BT20 TGX221 0 3 |
| BT-20 | TGX221 | 3 | 72 | 0.032 | 3002.3 | 3248.8 | 586.9 | -1.49 | 0.937 | 0.924 | 2.469 | BT20 TGX221 0 3 |
| BT-20 | TGX221 | 3 | 72 | 0.1 | 3280.8 | 3248.8 | 586.9 | -1.0 | 1.010 | 1.010 | 2.469 | BT20 TGX221 0 3 |